ArticleNeurosurgery2019
Craniotomy and Survival for Primary Central Nervous System Lymphoma.
Article in Neurosurgery, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed.
- CT Perfusion in the differential diagnosis of glioblastomas and primary central nervous system lymphomas.Neuroradiology · 2026Article
- Survival Outcomes and Prognostic Factors in Patients With Primary Central Nervous System Low-Grade B-Cell Lymphoma: A Population-Based Cohort Study.Cancer medicine · 2026Article
- Prediction of relapsed/refractory primary central nervous system lymphoma using pre-chemotherapy ITSS grade on SWI and pre-/post-chemotherapy ADC parameters on DWI.Cancer imaging : the official publication of the International Cancer Imaging Society · 2026Article
- Multiple primary central nervous system lymphoma in the ventricular system and interpeduncular cistern: A case report.Oncology letters · 2026Article
- Assessing the Effect of Cytoreduction on Solitary, Resectable Lesions in Primary Central Nervous System Lymphoma.Cancers · 2025Article
- Association between surgery and increased survival in primary central nervous system lymphoma: a retrospective cohort study.Scientific reports · 2025Article
- A case report of surgery-radiotherapy-chemotherapy cured primary diffuse large B-cell lymphoma of the central nervous system associated with HIV infection.Diagnostic pathology · 2024Article
- Advances in Primary Central Nervous System Lymphoma.Current neurology and neuroscience reports · 2024Review
- Survival outcomes and treatment experience of 124 patients with primary central nervous system lymphoma.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2024Article
- Diagnostics and treatment delay in primary central nervous system lymphoma: What the neurosurgeon should know.Acta neurochirurgica · 2024Review
- Histopathological Diagnosis of Primary Central Nervous System Lymphoma after Therapy with Corticosteroids or Anticoagulants.Cancers · 2024Article
- Article
- Primary central nervous system lymphoma: A mirror type presentation in an immunocompetent patient.Surgical neurology international · 2024Article
- MGMT promoter methylation in 1p19q-intact gliomas.Journal of neuro-oncology · 2024Article
- Multiple primary diffuse large B-cell lymphoma masquerading as meningioma.Surgical neurology international · 2024Article
- Influenza activity and regional mortality for non-small cell lung cancer.Scientific reports · 2023Article
- Analysis of False-negative Findings of the Incomparable Accuracy and Swiftness of Flow Cytometric Diagnosis of Primary Central Nervous System Lymphoma.Neurologia medico-chirurgica · 2023Article
- Article
- The role of comorbidity indices and histochemical markers in surgically resected and non-resected primary central nervous system lymphoma.Clinical and experimental medicine · 2023Article
- MGMT Promoter Methylation Predicts Overall Survival after Chemotherapy for 1p/19q-Codeleted Gliomas.Clinical cancer research : an official journal of the American Association for Cancer Research · 2023Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
15 authors.
Funding
Abstract
backgroundCytoreductive surgery is considered controversial for primary central nervous system lymphoma (PCNSL).
objectiveTo investigate survival following craniotomy or biopsy for PCNSL.
methodsThe National Cancer Database-Participant User File (NCDB, n = 8936), Surveillance, Epidemiology, and End Results Program (SEER, n = 4636), and an institutional series (IS, n = 132) were used. We retrospectively investigated the relationship between craniotomy, prognostic factors, and survival for PCNSL using case-control design.
resultsIn NCDB, craniotomy was associated with increased median survival over biopsy (19.5 vs 11.0 mo), independent of subsequent radiation and chemotherapy (hazard ratio [HR] 0.80, P < .001). We found a similar trend with survival for craniotomy vs biopsy in the IS (HR 0.68, P = .15). In SEER, gross total resection was associated with increased median survival over biopsy (29 vs 10 mo, HR 0.68, P < .001). The survival benefit associated with craniotomy was greater within recursive partitioning analysis (RPA) class 1 group in NCDB (95.1 vs 29.1 mo, HR 0.66, P < .001), but was smaller for RPA 2-3 (14.9 vs 10.0 mo, HR 0.86, P < .001). A surgical risk category (RC) considering lesion location and number, age, and frailty was developed. Craniotomy was associated with increased survival vs biopsy for patients with low RC (133.4 vs 41.0 mo, HR 0.33, P = .01), but not high RC in the IS.
conclusionCraniotomy is associated with increased survival over biopsy for PCNSL in 3 retrospective datasets. Prospective studies are necessary to adequately evaluate this relationship. Such studies should evaluate patients most likely to benefit from cytoreductive surgery, ie, those with favorable RPA and RC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.